Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million
PUBT · 1d ago
Share
Listen to the news
- Eurobio Scientific first-half revenue rose 4.5% to €84.5 million, while operating income climbed 45% to €8.5 million.
- Net income more than doubled to €4.7 million; EBITDA increased 20% to €15.8 million.
- Gross margin rate edged up 0.2 percentage points to 47.5%, and operating expenses fell to 35.1% of revenue from 37.2%.
- Free cash flow totaled €4 million, and net debt stood at €147.4 million, including the EB Development shareholder loan.
- CareDx’s Lab Solutions acquisition closed June 30, and EB Development proposed a tender offer at €25.30 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurobio Scientific SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241140OMX_____CNEWS_EN_GNW1001274457_en) on September 24, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending